AstraZeneca
AstraZeneca is a global biopharmaceutical company developing therapies in oncology, biopharmaceuticals, respiratory and rare diseases, with a 197-project pipeline and 16 marketed blockbuster medicines.
AstraZeneca is a global biopharmaceutical company that discovers, develops and commercialises therapies across oncology, biopharmaceuticals, respiratory and rare diseases. Founded in 1999 through the merger of two science-based companies, it focuses on precision medicine and next-generation therapeutics. Its technical work spans data science, artificial intelligence, cell therapies and pharmaceutical R&D, applied to problems in oncology research and rare disease therapeutics.
The scale of that work is substantial: 197 projects sit in the R&D pipeline, 16 blockbuster medicines are currently marketed, and the company has set an aspiration to deliver 20 new medicines by 2030. Billions are invested annually in research and development, supported by six strategic R&D centres.
Those centres are located in Cambridge (UK), Gothenburg (Sweden), Gaithersburg (USA), Boston (USA) and Shanghai and Beijing (China). AstraZeneca describes its approach as following the science, putting patients first and making values-driven decisions - a culture it traces back to its 1999 merger.